List today: Mission Produce, Inc. AVO: This fruits producer has seen the Zacks Consensus Estimate for its current year ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 29th: GDS Holdings Limited GDS: This data center operator from China has a Zacks Rank #1 ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of ...

The UK's life sciences plan has led to a split in opinions based within the pharma sector. A more detailed guide on what this ...

Fiction has been preparing us for an unseen, all knowing CEO for decades. Now technology could make it reality.

Africa is building a new vaccine future through strategic investments, skilled workforce development, and local manufacturing ...

Sound more like science fiction than actual science? Then, brace yourself because there are, at least, 15 breast cancer vaccine clinical trials in various stages in the U.S., some in phase II and III.

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...